US · Healthcare

Lyra Therapeutics Inc (LYRA)

Biotechnology

Lyra Therapeutics Inc (LYRA) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for LYRA

P/E ratio

25.00

Lyra Therapeutics Inc (LYRA) — FAQ

What is LYRA's P/E ratio?

The price-to-earnings (P/E) ratio for Lyra Therapeutics Inc (LYRA) is 25.00 (data as of 2026-05-23).

Does Lyra Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Lyra Therapeutics Inc (LYRA). Check the MyAverix Finance app for the latest dividend data.

What sector is Lyra Therapeutics Inc in?

Lyra Therapeutics Inc (LYRA) is classified in the Healthcare sector (Biotechnology industry).

What exchange is LYRA listed on?

LYRA is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)